Nandita Kachru1, Ryan M Carnahan2, Michael L Johnson1, Rajender R Aparasu3. 1. Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX. 2. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City. 3. Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX. Electronic address: rraparasu@uh.edu.
Abstract
OBJECTIVE: To examine the prevalence and predictors of potentially inappropriate anticholinergic medication use in older adults with dementia. DESIGN: A cross-sectional study. SETTING: United States, 2009-2010. PARTICIPANTS: Medical Expenditure Panel Survey household component participants aged 65 years or older identified as having dementia and using potentially inappropriate anticholinergic medication. MAIN OUTCOME MEASURES: Prevalence and predictors of potentially inappropriate anticholinergic medication use as per the updated 2012 American Geriatrics Society Beers criteria. RESULTS: A total of 3.78 million older adult patients (95% confidence interval [CI] 3.17 million to 4.38 million) were identified as having dementia, for an overall prevalence of 4.81%. Of those patients, an estimated 1.02 million (95% CI 0.70 million to 1.30 million) were reported to use potentially inappropriate anticholinergic medications, for an overall prevalence of 26.95% (95% CI 20.10% to 33.79%). The most frequently prescribed drugs were oxybutynin, solifenacin, paroxetine, tolterodine, promethazine, and cyclobenzaprine. Multivariable logistic analysis revealed that those patients with the need characteristics of self-reported anxiety, mood disorders, and "fair/poor" general health status had increased odds of potentially inappropriate anticholinergic use, while patients with the predisposing characteristic of being aged 75-84 years had decreased odds of potentially inappropriate anticholinergic use. CONCLUSION: More than one in four older adults with dementia were found to use potentially inappropriate anticholinergics. Given the adverse cognitive effects of these medications, there is a strong need to monitor and optimize their use in older adult patients with dementia.
OBJECTIVE: To examine the prevalence and predictors of potentially inappropriate anticholinergic medication use in older adults with dementia. DESIGN: A cross-sectional study. SETTING: United States, 2009-2010. PARTICIPANTS: Medical Expenditure Panel Survey household component participants aged 65 years or older identified as having dementia and using potentially inappropriate anticholinergic medication. MAIN OUTCOME MEASURES: Prevalence and predictors of potentially inappropriate anticholinergic medication use as per the updated 2012 American Geriatrics Society Beers criteria. RESULTS: A total of 3.78 million older adult patients (95% confidence interval [CI] 3.17 million to 4.38 million) were identified as having dementia, for an overall prevalence of 4.81%. Of those patients, an estimated 1.02 million (95% CI 0.70 million to 1.30 million) were reported to use potentially inappropriate anticholinergic medications, for an overall prevalence of 26.95% (95% CI 20.10% to 33.79%). The most frequently prescribed drugs were oxybutynin, solifenacin, paroxetine, tolterodine, promethazine, and cyclobenzaprine. Multivariable logistic analysis revealed that those patients with the need characteristics of self-reported anxiety, mood disorders, and "fair/poor" general health status had increased odds of potentially inappropriate anticholinergic use, while patients with the predisposing characteristic of being aged 75-84 years had decreased odds of potentially inappropriate anticholinergic use. CONCLUSION: More than one in four older adults with dementia were found to use potentially inappropriate anticholinergics. Given the adverse cognitive effects of these medications, there is a strong need to monitor and optimize their use in older adult patients with dementia.
Authors: Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu Journal: Curr Med Res Opin Date: 2021-05-13 Impact factor: 2.705
Authors: Ashley I Martinez; Erin L Abner; Gregory A Jicha; Dorinda N Rigsby; Lynne C Eckmann; Mark J Huffmyer; Daniela C Moga Journal: J Manag Care Spec Pharm Date: 2020-04